The real problem for the shorts... My personal
Post# of 72446
(Total Views: 256)
Posted On: 06/28/2017 2:32:07 PM
The real problem for the shorts...
My personal belief is that IPIX will be partnered for P first and I also think this is the strategic plan of IPIX. If you follow the comments made by Art, K will be partnered after the 2a trial and they are able to make an oral formulation of K.
Which leaves B. My belief is that IPIX wants to develop B further before partnering because of the potential indications (which is staggering), to fully realize it's potential value (right now it would actually be hard to price)....
but what is the problem for shorts...
The problem is that Leo CAN partner B. The UP trial is complete. The safety profile is well known because B has been IV'd and systemic exposure has already been proven safe at much higher levels. The OM trial is also de-risking the spontaneous remission risk in the UP trial. Our preliminary results in OM are already showing a strong discrepancy between B and placebo. When the difference is so large, even small samples can demonstrate statistical significance.
If you read the June conference transcript, Leo mentions the possibility of partnering for a single indication. This would not be possible without a completed trial and now we have the word that UP is complete. Next would be: what about the safety? We know the absorption levels and know that much higher levels were safe in the ABSSSI trial, so that is not a concern. Finally, we already have preliminary indications that the placebo-controlled OM trial, B is actually showing signs of working. And all of that leads to the problem for shorts which is...
Not that Leo WILL partner now for B, but that Leo CAN.
My personal belief is that IPIX will be partnered for P first and I also think this is the strategic plan of IPIX. If you follow the comments made by Art, K will be partnered after the 2a trial and they are able to make an oral formulation of K.
Which leaves B. My belief is that IPIX wants to develop B further before partnering because of the potential indications (which is staggering), to fully realize it's potential value (right now it would actually be hard to price)....
but what is the problem for shorts...
The problem is that Leo CAN partner B. The UP trial is complete. The safety profile is well known because B has been IV'd and systemic exposure has already been proven safe at much higher levels. The OM trial is also de-risking the spontaneous remission risk in the UP trial. Our preliminary results in OM are already showing a strong discrepancy between B and placebo. When the difference is so large, even small samples can demonstrate statistical significance.
If you read the June conference transcript, Leo mentions the possibility of partnering for a single indication. This would not be possible without a completed trial and now we have the word that UP is complete. Next would be: what about the safety? We know the absorption levels and know that much higher levels were safe in the ABSSSI trial, so that is not a concern. Finally, we already have preliminary indications that the placebo-controlled OM trial, B is actually showing signs of working. And all of that leads to the problem for shorts which is...
Not that Leo WILL partner now for B, but that Leo CAN.
(6)
(0)